Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

CD4 + T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism

Matteo Bellone, MD, Paolo Dellabona, MD PhD, Arianna Calcinotto, BS, Giulia Casorati, PhD, Alessandra Rovida, PhD, Maria Teresa Sabrina Bertilaccio, PhD, Elena Cattaneo, Matteo Grioni, Federico caligaris-Cappio, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 683.

https://doi.org/10.1182/blood-2019-128246

Published: 2019

Journal Articles

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps

Blood (2018) 131 (25): 2745–2760.

https://doi.org/10.1182/blood-2017-09-806398

Published: 2018

Journal Articles

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis

Francesca Gorini, Laura Azzimonti, Gloria Delfanti, Lydia Scarfò, Cristina Scielzo, Maria Teresa Bertilaccio, Pamela Ranghetti, Alessandro Gulino, Claudio Doglioni, Arianna Di Napoli, Miriam Capri, Claudio Franceschi, Federico Caligaris-Cappio, Paolo Ghia, Matteo Bellone, Paolo Dellabona, Giulia Casorati, Claudia de Lalla

Blood (2017) 129 (26): 3440–3451.

https://doi.org/10.1182/blood-2016-11-751065

Published: 2017

Includes: Supplemental data

Journal Articles

HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment

Roberta Valsecchi, Nadia Coltella, Daniela Belloni, Manfredi Ponente, Elisa ten Hacken, Cristina Scielzo, Lydia Scarfò, Maria Teresa Sabrina Bertilaccio, Paola Brambilla, Elisa Lenti, Filippo Martinelli Boneschi, Andrea Brendolan, Elisabetta Ferrero, Marina Ferrarini, Paolo Ghia, Giovanni Tonon, Maurilio Ponzoni, Federico Caligaris-Cappio, Rosa Bernardi

Blood (2016) 127 (16): 1987–1997.

https://doi.org/10.1182/blood-2015-07-657056

Published: 2016

Includes: Supplemental data

Journal Articles

IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment

Elisa ten Hacken, PhD, Mariela Sivina, PhD, Li Ping, PhD, Susan O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael J. Keating, MD, Cristina Scielzo, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Jan A. Burger, MD PhD

Blood (2015) 126 (23): 2915.

https://doi.org/10.1182/blood.V126.23.2915.2915

Published: 2015

Journal Articles

Directing CLL-cell traffic

Federico Caligaris-Cappio

Blood (2015) 126 (11): 1267–1268.

https://doi.org/10.1182/blood-2015-07-657890

Published: 2015

Journal Articles

Anergy in CLL: Moving Towards the Clinic

Benedetta Apollonio, Tania Veliz Rodriguez, Cristina Scielzo, PhD, Maria Teresa Sabrina Bertilaccio, Lydia Scarfò, Federico Caligaris-Cappio, MD, Paolo Ghia, MD PhD

Blood (2014) 124 (21): 4677.

https://doi.org/10.1182/blood.V124.21.4677.4677

Published: 2014

Journal Articles

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Michael Steurer, MD, Marco Montillo, MD, Lydia Scarfò, Francesca Romana Mauro, Johannes Andel, MD, Sophie Wildner, MD, Livio Trentin, MD, Ann Janssens, MD, Sonja Burgstaller, MD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Marco Gobbi, MD

Blood (2014) 124 (21): 1996.

https://doi.org/10.1182/blood.V124.21.1996.1996

Published: 2014

Journal Articles

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

Andrés J.M. Ferreri, Giovanni Donadoni, MD, Maria Giuseppina Cabras, MD, Caterina Patti, MD, Michael Mian, Renato Zambello, MD, Corrado Tarella, MD, Massimo Di Nicola, MD, Alfonso D'Arco, Gianluca Doa, Marta Bruno-Ventre, Marco Foppoli, MD, Alessandro Fanni, MD, Antonino Mulè, MD, Fabio Ciceri, MD, Federico Caligaris-Cappio, MD

Blood (2014) 124 (21): 1724.

https://doi.org/10.1182/blood.V124.21.1724.1724

Published: 2014

Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 3331.

https://doi.org/10.1182/blood.V124.21.3331.3331

Published: 2014

Journal Articles

Nurse-like Cells Engage Sigm and Sigd on Chronic Lymphocytic Leukemia (CLL) Cells: Implications for BCR Signaling Activation and Functional Outcome

Elisa ten Hacken, PhD, Cristina Scielzo, PhD, Susan O'Brien, MD, William G. Wierda, MD PhD, Michael Keating, MBBS, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Jan A. Burger, MD PhD

Blood (2014) 124 (21): 3312.

https://doi.org/10.1182/blood.V124.21.3312.3312

Published: 2014

Journal Articles

Anergy: the CLL cell limbo

Federico Caligaris-Cappio

Blood (2014) 123 (21): 3214–3215.

https://doi.org/10.1182/blood-2014-04-565408

Published: 2014

Journal Articles

Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia

Elisa ten Hacken, Cristina Scielzo, William G. Wierda, MD, PhD, Michael J. Keating, MD, Susan O'Brien, MD, Paolo Ghia, MD, PhD, Federico Caligaris-Cappio, MD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 4143.

https://doi.org/10.1182/blood.V122.21.4143.4143

Published: 2013

Journal Articles

Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo

Maria Teresa Sabrina Bertilaccio, Sarah Tettamanti, PhD, Greta Maria Paola Giordano Attianese, PhD, Giovanni Galletti, Silvia Arcangeli, Tania Veliz Rodriguez, Chiara Francesca Magnani, PhD, Federica Barbaglio, Lydia Scarfò, MD, Maurilio Ponzoni, MD, Andrea Biondi, MD, Federico Caligaris-Cappio, MD, Ettore Biagi, MD, PhD, Paolo Ghia, MD, PhD

Blood (2013) 122 (21): 4171.

https://doi.org/10.1182/blood.V122.21.4171.4171

Published: 2013

Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Marco Gobbi, MD, Michael Steurer, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Ann Janssens, MD, Livio Trentin, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD

Blood (2013) 122 (21): 1635.

https://doi.org/10.1182/blood.V122.21.1635.1635

Published: 2013

Journal Articles

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Marta Bruno Ventre, MD, Marco Foppoli, MD, Giovanni Citterio, MD, Giovanni Donadoni, MD, Maurilio Ponzoni, MD, Silvia Govi, MD, Lydia Scarfò, MD, Marianna Sassone, MD, Federico Caligaris -Cappio, MD, Prof., Andres J.M. Ferreri, MD, PhD

Blood (2013) 122 (21): 4365.

https://doi.org/10.1182/blood.V122.21.4365.4365

Published: 2013

Journal Articles

Targeting B-cell anergy in chronic lymphocytic leukemia

Benedetta Apollonio, Cristina Scielzo, Maria Teresa Sabrina Bertilaccio, Elisa ten Hacken, Lydia Scarfò, Pamela Ranghetti, Freda Stevenson, Graham Packham, Paolo Ghia, Marta Muzio, Federico Caligaris-Cappio

Blood (2013) 121 (19): 3879–3888.

https://doi.org/10.1182/blood-2012-12-474718

Published: 2013

Includes: Supplemental data

Journal Articles

Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia

Elisa ten Hacken, Cristina Scielzo, Maria T. S. Bertilaccio, Lydia Scarfò, Benedetta Apollonio, Federica Barbaglio, Kostas Stamatopoulos, Maurilio Ponzoni, Paolo Ghia, Federico Caligaris-Cappio

Blood (2013) 121 (12): 2264–2273.

https://doi.org/10.1182/blood-2012-09-457119

Published: 2013

Includes: Supplemental data

Journal Articles

Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL

Cristina Maccalli, Maria Gounari, Kostas Stamatopoulos, Federico Caligaris-Cappio, MD, Giorgio Parmiani, Paolo Ghia

Blood (2012) 120 (21): 1775.

https://doi.org/10.1182/blood.V120.21.1775.1775

Published: 2012

Journal Articles

Targeting the LYN/HS1 Signaling Axis in Chronic Lymphocytic Leukemia

Elisa ten Hacken, Cristina Scielzo, Maria Teresa Sabrina Betilaccio, Lydia Scarfò, MD, Benedetta Apollonio, Maurilio Ponzoni, Kostas Stamatopoulos, Paolo Ghia, Federico Caligaris-Cappio, MD

Blood (2012) 120 (21): 928.

https://doi.org/10.1182/blood.V120.21.928.928

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD4 + T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis

HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment

IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment

Directing CLL-cell traffic

Anergy in CLL: Moving Towards the Clinic

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurse-like Cells Engage Sigm and Sigd on Chronic Lymphocytic Leukemia (CLL) Cells: Implications for BCR Signaling Activation and Functional Outcome

Anergy: the CLL cell limbo

Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia

Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Targeting B-cell anergy in chronic lymphocytic leukemia

Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia

Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL

Targeting the LYN/HS1 Signaling Axis in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology